## 3 Results and Discussions
### Cytotoxic Study  
Initially, the prepared compounds **3a-3j** are screened for their _in-vitro_ anticancer activity against the human colon carcinoma cell line (HCT-116) and the human breast cancer cell line (MDA-MB-231), according to the literature protocol [47]. The cell lines are cultured with DMEM supplemented with 10% FBS, L-glutamine, sodium bicarbonate, and an antibiotic solution containing penicillin (100 U/mL) and streptomycin (100 ug/mL). All cell lines are maintained in culture at 37 \({}^{\circ}\)C in an atmosphere of 5% carbon dioxide. The as-synthesized indazoles **3a-3j** are screened for in vitro cytotoxic activity against HCT-116 and MBA-MB-231 cell lines. The anticancer properties of these analogs, i.e., **3a-3j**, are compared with the standard doxorubicin. IC\({}_{50}\) values of the test compound for 24 h on each cell line are calculated and presented in Table 3.  
It is evident from the results that the tested indazole compounds **3c**, **3g**, and **3i** are found to be more potent against the HCT-116 cell line than the MDA-MB-231 cell line. However, the test compound **3j** possesses potent cytotoxic activity against both the cell lines tested, i.e., HCT-116 and MDA-MB-231 at IC\({}_{50}\) < 87 ug/mL. Very few of the 3-aryl-1-\(H\)-indazole compounds (**3h** and **3c**) are found to be moderately active against the two cell lines tested. The test compound **3j** showed good activity against the HCT-116 cell line. The test compounds **3c** and **3h** exhibited almost similar activity against the HCT-116 cell line with IC\({}_{50}\) < 94 ug/mL. The compounds **3h** and **3c** are found to be moderately active against the cell line  
\begin{table} \begin{tabular}{c c c} \hline \multirow{2}{*}{**Compound**} & \multicolumn{2}{c}{**IC\({}_{50}\) (ug/mL)**} \\ \cline{2-3}  & **HCT-116** & **MDA-MB-231** \\ \hline
**3a** & – & – \\ \hline
**3b** & – & – \\ \hline
**3c** & \(92.9\pm 6.5\) & \(102.3\pm 13.2\) \\ \hline
**3d** & \(127.6\pm 3.8\) & \(117.5\pm 15.0\) \\ \hline
**3e** & – & – \\ \hline
**3f** & \(109.6\pm 12.3\) & \(107.4\pm 10.0\) \\ \hline
**3g** & \(106.6\pm 14\) & \(112.2\pm 17.9\) \\ \hline
**3h** & \(93.6\pm 7.2\) & \(95\pm 6.8\) \\ \hline
**3i** & \(102\pm 11.1\) & \(120.1\pm 7.2\) \\ \hline
**3j** & \(85.3\pm 16.7\) & \(87\pm 5.2\) \\ \hline
**Standard \({}^{*}\)** & \(1.2\pm 0.3\) & \(0.3\pm 0.1\) \\ \hline \end{tabular}  \({}^{*}\)\(MDA-MB-231 with IC\({}_{50}\) < 96 and IC\({}_{50}\) < 103 \(\mu\)g/mL, respectively. Unfortunately, the compounds **3a**, **3b**, and **3e** are found to be inactive against the tested two cell lines. After the screening of the cytotoxic properties of 3-aryl indazoles **3a-3j**, the studies were extended to the evaluation of cytotoxic properties of the final compound i.e., \(N\)-methyl-3-aryl indazoles **5a-5j** against the cancer cell lines HCT-119 and MDA-MB-231, according to the same literature protocol [47] employed above. The IC\({}_{50}\) values of the test compounds are compared with the standard doxorubicin and the results of investigation were presented in Table 4. The IC\({}_{50}\) value of the standard doxorubicin is 1.2 \(\mu\)g/mL against the HCT-116 cell line, 0.3 \(\mu\)g/mL against the MDA-MB-231 cell line. The tested compounds **5a-5j** showed their IC\({}_{50}\) values in between 54.1-172.4 \(\mu\)g/mL. All the obtained compounds displayed moderate to mild cytotoxic than the standard as evident from their higher IC\({}_{50}\) values. From the above studies, it can be found that doxorubicin is more potent than the tested compounds; however, the structure related activity study of tested compounds can be used to guide us to develop potent molecules. A graphical illustration for the obtained IC\({}_{50}\) values for the compounds **3a-3j** and **5a-5j** is given in Figure 3.